SPARC (SPARC)

FairStock Score: 36/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor, so I start with the numbers and ask whether the business is understandable, profitable, and conservatively priced. SPARC sits in pharmaceuticals, but the latest quarter shows Sales of only ₹8 Cr against a Net Loss of ₹81 Cr. A ₹6,425 Cr market cap therefore rests on future hopes, not current earnings. The headline P/E of 4.06 looks tempting, but with negative quarterly profit and ROCE of -297.83%, I treat it as misleading. The ROE of 338.67% is similarly not a sign of quality when ROCE is deeply negative; it likely reflects accounting distortion rather than durable returns on capital. Debt/Equity of 0.42 is not alarming, and promoter holding of 65.67% aligns owners with shareholders. Sales Growth of 113.93% and 5yr Revenue CAGR of 49.33% show top-line momentum, but from a tiny base. Profit Growth of 59.68% also conflicts with current losses. P/B of 4.80 on Book Value of ₹41.26 means I am paying nearly five times book for a loss-making business. No dividend adds to the lack of cash return. FairStock Score 36/100 and Piotroski F-Score 5/9 confirm mixed quality. I would not buy this as a Buffett-style compounder. If I were to watch it, it is only as a turnaround speculation: I need to see consistent profits, positive ROCE, and sales converting into cash. Until then, the 52-week range of ₹108-₹289 reflects volatility, not value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer